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Abstract
The objective of this research was to determine the effect of black cumin seed oil (BCSO) on hematology,
level of aspartat aminotransferase (AST)/alanin aminotransferase (ALT), level of ureum and creatinine,
and also immune response in healthy subjects. This study applied a phase 1 of clinical trial. The 36
healthy subjects were divided into three groups, 12 subjects each group. Group I, subjects received 1 × 3
soft capsules of BCSO. Group II, subject received 2 × 3 soft capsules of BCSO and in groups III subject
received 3 × 3 soft capsules of BCSO. Each soft capsule contained of 0.5 ml standardized BCSO. On the
21st day, the blood cell, level of ALT and AST and level of ureum and creatinine were measured. The
average number of blood cells, levels of ALT/AST and level of ureum and creatinine then were been
analyzed with one way ANOVA test. Statistical analysis was performed on 95% confidence level. The
results showed that the administration of three doses of BCSO soft capsule did not increase number of
blood cells, level of ALT/AST and level of ureum and creatinine (p>0.05). BCSO also did not affect
number of CD4+ Th and CD4+CD25+ Treg cells and also expression of IFN-γ (p>0.05). The
consumption of BCSO at three doses 1.5, 3, and 4.5 ml/d for 21 days in healthy subjects were tolerable
and safety.
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Introduction
Black cumin seed oil (BCSO) has often been used by people as
an alternative and complementary medicine. BCSO contains a
lot of unsaturated fatty acids such as linoleic acid and linolenic
acid. It also contains of essential oil with active substances
such as thymoquinone, and nigellone (dithymoquinone) [1-3].
Unsaturated fatty acids and thymoquinone are powerful
antioxidants and immunomodulatory agents [4-7]. The
mechanism actions of antioxidant and anti-inflammatory
effects of BCSO have been investigated both in preclinical
[8-10] and clinical studies [11-13].
Unfortunately, the administration of a combination of BCSO
and other herbal preparations has been reported cause hepatic
dysfunction in Indonesia. Furthermore, the administration of a
combination between BCS and Phyllantus niruri increases the
activity of ALT and AST in hospitalized-patients. But, other
clinical trials showed that 300-500 mg/d of BCS powders
supplied with standard drugs in patients improve the profile
blood cholesterol, lowering the percentage of HbA1C and
blood pressure in patients menopause and non-menopause and
is not accompanied by increase in SGPT and SGOT or their
harmful side effects [14-16].
This study was aimed to determine the effect of BCSO at dose
of 1.5, 3 and 4.5 ml/d for 20 days on peripheral blood, liver
and kidney function in healthy subjects to study the safety of
BCSO. The influence of BCSO on immune responses was
observed by measuring the expression of IFN-γ in T
lymphocytes and the number of CD4+ Th and CD4+CD25+
Treg cells. In this study, BCSO was prepared in soft capsules to
be more acceptable by the subjects.
Methods
Materials
BCSO was standardized for the concentration of thymoquinone
and then was formed in soft capsules immunax (SCI).
Specification of BCSO is presented in Table 1. The capsules
were given to the subjects orally daily at 1.5 ml (1 × 3 SCI), 3
ml (2 × 3 SCI) and 4.5 ml (3 × 3 SCI).
Table 1. The content of BCSO in the soft capsules immunax (SCI).
Content of BCSO Relative concentration (%)
Thymoquinone 2.72
Caprilic acid 0.21
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Capric acid 0.15
Lauric acid 0.1
Myristic acid 0.18
Palmitic acid 12.27
Palmitoleic acid 0.28
Heptadecanoic acid 0.1
Oleic acid 0.07
Linoleic acid 2.85
Linolenic acid 0.1
Eicosanoic acid 3.15
Eicosenic acid 0.15
Eicosadienoic acid 0.25
Arachidonic acid 0.03
Eicopentanoic acid 0.03
Behenic acid 0.06
Docoheksanoic acid 0.04
Teracosanoic acid 0.02
Subjects
The inform consent and the ethical clearance for this study was
reviewed and approved by Research Ethics Committee, Ahmad
Dahlan University (No: 011503029). Respondents for the study
were selected based on the inclusion and exclusion criteria.
The inclusion criteria were men/women aged 18-60, be healthy
evidenced by a health certificate, and willing to be the
respondent (by filling the informed consent). The exclusion
criteria were woman pregnancy and hypersensitive history to
ingredient of Nigella sativa oil. Physical examination and
clinical examination of prospective subjects are conducted to
ascertain the health status.
Recruitment of subjects
The brochures/leaflets, the recruitment procedure, the informed
consent, the research procedures as well as case report form
have been reviewed and approved by the Ethics Committee of
Ahmad Dahlan University. Researchers distributed the
brochures and the announcement about the recruitment of
volunteers of BCSO safety testing in the campus of Ahmad
Dahlan University and Gadjah Mada University as well as in
some public facilities in Yogyakarta. Interested people should
call on the phone number listed in the brochure or leaflet. For
prospective volunteers who have signed up are then invited for
an explanation of the purpose, benefits, and procedures as well
as the consequences and the rights of research volunteers. After
signing the informed consent, the subjects performed a
physical and clinical examination to ascertain their health
status. A total of 36 volunteers received health certificates and
signed the informed consents.
Experimental design
A total of 36 healthy subjects were randomly divided into three
experimental groups. Group 1 was given 1 × 3 BCSO soft
capsules (SC) (1.5 ml/d), group 2 was given 2 × 3 BCSO SC (3
ml/d) and group 3 was given 3 × 3 BCSO SC (4.5 ml/d).
BCSO SC were orally administered every day for 20 days. In
day 21, the peripheral blood, the levels of AST/ALT, BUN and
creatinine level, number of CD4+ Th and CD4+ CD25+ Treg
cells and expression of IFN-γ were determined.
Blood pressure and heart rate measurement
Measurement of blood pressure and heart rate is performed
three times during the study by professionals. Blood pressure
was measured in the left arm using a mercury
sphygmomanometer, supine sleeping position, wide cuff
adapted to the size of the arm, as recommended by WHO. Each
blood pressure measurement was repeated 2 times with 30
minutes interval time between measurements. The heart rate
was calculated on the radial artery and repeated 3 times. The
value of blood pressure and heart rate were presented as
average value.
Peripheral blood, renal and liver function analysis
Peripheral blood was taken and collected from the cubital vein
by authorized analyst. The blood was then examined for the
peripheral blood and kidney function by measuring level of
urea and creatinine using hematoanalyzer as performed in a
previous study [17].
Expression of IFN-γ and number of CD3+CD4+ Th
and CD3+CD4+CD25+ treg cells analysis
Immune response was observed by measuring the expression
of IFN-γin T lymphocytes and the number of CD4+ Th and
CD4+CD25+ Treg cells. IFN-γ expression and the number of
CD4+ Th and CD4+CD25+ Treg cells been measured using
flow cytometry.
Data analysis
The significant difference between groups was tested by one
way Anova analysis. The difference intern group before and
after treatment were tested by two-way ANOVA. The
statistical test was performed at 95% confidence level. The
average difference in blood pressure and heart rate between
measurements in one group was analyzed with repeated
ANOVA.
Results
Demographic characteristic of respondents
Respondents who participated in this study are 36 subjects
consisting of 10 (22.92%) men and 26 (77.08%) women.
Characteristics of the respondents are presented in Table 2.
Respondents in this study aged 18-60 years. Based on body
mass index (BMI), there were 15 (40.83%) people having BMI
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<25 (non-obese) and 21 (59.17%) subjects having BMI ≥ 25
(obese). Based on a history of hypertension owned
respondents, there were 2 (5.17%) people with history of
hypertension and 34 (94.83%) had no history of hypertension.
Based on the level of education, respondents who had finished
high school were 9 (25.00%) people and 27 (75%) respondent
have passed university. While based on marital status, 5
(14.58%) respondents are categorized as married and 31
(85.42%) people are unmarried. Statistically the sex, age, BMI,
history of hypertension, education, occupation and marital
status of respondents were not different (p>0.05).
Table 2: Characteristic of respondents consummated BCSO 1.5; 3; 4.5
ml/d.
Characteristic of the respondents n % p
Sex
Men 10 27.8
0.35
Women 26 72.2
Age
≤ 25 years 30 83.33
0.947
>25 years 6 16.67
Body mass index (BMI)
<25 (kg/cm2) 15 41.7
0.918
≥ 25 (kg/cm2) 21 58.3
History of Hypertension
Yes 2 4.17
0.837
No 34 95.83
Education
High School 9 25.00
0.056
Graduate program 27 75
Occupation
Student 28 79.17
0.734Non-government 6 14.58
entrepreneur 2 6.25
Marital status
Married 5 14.58
0.673
Not married 31 85.42
Health assurance
Private health assurance 3 8.3 0.056
Public heath assurance 10 27.8
Not health assurance 23 63.9
Clinical characteristic of respondents
The clinical condition of the volunteers before treatment are
presented in Table 3. As shown in Table 3, the clinical
condition of the subject prior to the administration BSCO
under similar conditions. Levels of hemoglobin, number of
erythrocytes, leukocytes and platelets within the normal range
and comparable between treatment groups (p>0.05). The
results of the number of leukocytes to monocytes, neutrophils,
eosinophils and basophils in all three groups were comparable
(p>0.05).
Table 3: Clinical characteristics of the healthy subject before BSCO
administration.
Clinical characteristic
Treatment Groups p
Group I
(n=12)
Group II
(n=12)
Group III
(n=12)
Age (years) 25.83 ± 6.58 24.08 ± 4.48 23.83 ± 4.45 0.6
Body Weight (Kg) 57.42 ±11.33
58.00 ±
16.18
61.50 ±
17.66 0.8
Pulse (frex/menutes) 73.00 ± 4.39 76.16 ± 7.79 75.50 ± 5.60 0.6
Systolic blood pressure
(mmHg)
116.25 ±
16.80
117.00 ±
14.19
114.35 ±
17.89 0.8
Diastolic Blood Pressure
(mmHg)
73.75 ±
10.02
73.33 ±
13.70
73.75 ±
12.45 0.7
Hb (pg) 13.28 ±13.28 13.04 ± 1.17 14.19 ± 0.74 0.6
Erithrocytes (×106/mL) 4.885 ± 0.37 5.02 ± 0.43 5.15 ± 0.51 0.2
Leucocytes (×103/mL) 8.22 ± 2.05 7.42 ± 1.68 9.26 ± 4.45 0.5
Thrombocytes (×103/mL) 311.17 ±73.73
302.17 ±
85.96
299.90 ±
56.35 0.6
Limphocytes (%) 30.58 ± 4.85 36.41 ± 8.48 31.67 ± 9.61 0.6
Monocytes (%) 7.67 ± 1.30 7.00 ± 1.28 6.17 ± 1.11 0.3
Neutrophil (%) 57.92 ± 6.68 53.83 ± 9.67 59.42 ±10.48 0.8
Eosinophil (%) 3.83 ± 2.62 2.75 ± 1.76 2.75 ± 1.54 0.9
ESR hour 1 (mm/h) 14.92 ±11.06
16.33 ±
12.87
15.67 ±
12.18 0.8
ESR hour 2 (mm/h) 34.67 ±24.42
32.75 ±
22.17
32.25 ±
20.33 0.9
MCV (fl) 81.94 ± 7.02 81.49 ± 7.82 83.02 ± 5.67 0.5
MCH (pg) 27.41 ± 2.63 26.81 ± 3.48 27.75 ± 1.90 0.5
MCHC (%) 33.44 ± 0.72 32.82 ± 1.41 33.45 ± 0.66 0.4
RDW (%) 13.77 ± 1.86 13.66 ± 1.75 13.05 ± 0.78 0.6
Glucose (mg/dl) 89.17 ±13.23
94.33 ±
14.67
93.33 ±
16.52 0.7
Total cholesterole (mg/dl) 177.00 ±23.33
197.25 ±
24.38
183.67 ±
31.26 0.2
Triglyceride (mg/dl) 97.08 ±34.91
149.33 ±
95.34
99.42 ±
53.89 0.1
ALT (mg/dl) 23.58 ±29.26
18.03 ±
16.80
20.06 ±
17.69 0.9
AST (mg/dl) 22.47 ±21.51
20.76 ±
11.62 19.19 ± 9.18 0.9
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BUN (mg/dl) 7.96 ± 1.80 8.43 ± 2.31 7.55 ± 2.31 0.4
Creatinine (mg/dl) 0.71 ± 0.11 077 ± 0.16 0.76 ± 0.16 0.5
IFN-γ (%) 3.06 ± 1.95 2.19 ± 1.51 3.44 ± 2.86 0.6
CD4+ Th Cells (%) 46.19 ± 7.55 41.49 ± 8.61 39.30 ± 9.17 0.6
CD4+CD25+ Treg Cells
(%) 24.30 ± 6.71 28.30 ± 9.50 25.20 ± 6.17 0.5
Analysis of blood pressure and heart rate
In this research, monitoring clinical conditions of the
respondents included blood pressure and heart rate. Clinical
examination includes blood pressure, temperature; rhythm and
heart rate were performed on day 0, 10 and 20. The average of
blood pressure of the respondents is presented in Table 4.
Table 4: The average of blood pressure between control and treatment
groups treated by BCSO.
Groups Parameters Blood pressure (mmHg) and pulse
(frex/men) (mean ± SD)
p
Control Day 10 Day 20
Group I
(n=12)
Systolic BP
(mmHg)
116.25 ±
16.80
109.50 ±
11.29
110.83 ±
11.64 >0.05
Diastolic BP
(mmHg)
73.75 ±
10.02
70.08 ±
7.26
69.58 ±
9.40 >0.05
Pulse (frex/menut) 73.00 ±4.39
75.00 ±
5.42
76.33 ±
8.97 >0.05
Group II
(n=12)
Systolic BP
(mmHg)
117.00 ±
14.19
116.67 ±
14.03
112.50 ±
12.88 >0.05
Diastolic BP
(mmHg)
73.33 ±
13.70
70.00 ±
9.04
65.83 ±
11.83 >0.05
Pulse (frex/menit) 76.16 ±7.79
78.33 ±
8.97
74.16 ±
7.00 >0.05
Group III
(n=12)
Systolic BP
(mmHg)
114.35 ±
17.89
112.08 ±
14.37
107.92 ±
16.98 >0.05
Diastolic BP
(mmHg)
73.75 ±
12.45
72.91 ±
9.40
70.41 ±
12.14 >0.05
Pulse (frex/menit) 75.50 ±5.60
74.83 ±
5.74
77.33 ±
7.92 >0.05
Overall, the average of the systole and diastole blood pressure
both on day 0 and day 10 was not significant (p>0.05). While
there was a significant difference in the average of blood
pressure on day 0 and day 10 compared to day 20 both systole
and diastole (p<0.05). However, there are no significant
differences in the average blood pressure in both systole and
diastole between the groups treated with control (p>0.05).
BCSO did not significantly affect to the blood pressure and
heart rate than the control group. Thus, the consumption of
BCSO for 20 days does not significantly affect blood pressure
in healthy subjects.
Blood composition and liver & renal function analysis
The administration of 1 × 3, 2 × 3 and 3 × 3 SC BCSO for 20
days in healthy respondents did not affect the blood
components. The number of blood cells such as leukocytes,
erythrocytes and platelets within normal limits and there was
no significant difference between treatment groups (p>0.05).
The normal value of hemoglobin is >13 ml/dl in men or >12
mg/dl in women. Hb value of all groups was >13 mg/dl. The
number of erythrocytes for normal condition is 3-7 × 103
cell/dl. The number of erythrocytes in all groups was >4 ×106
cells/dl. The results showed that administration of a 1 × 3, 2 ×
3 and 3 × 3 BCSO SC in healthy respondents did not affect
blood cell number.
Table 5. The clinical characteristic of healthy subject after administration 1.5, 3 and 4.5 ml/day BCSO for 20 days (each group n=12 subject).
Blood components Treatment groups p
Group1 treated 1.5 ml BCSO Group2 treated 3 ml BCSO Group3 treated 4.5 ml
BCSO
Hemoglobin (pg) 13.33 ± 1.47 13.62 ± 1.60 14.12 ± 0.57 >0.05
Erythrocyte (× 106/ml) 4.87 ± 0.31 5.09 ± 0.41 5.06 ± 0.46 >0.05
Hematocrit (%) 39.53 ± 3.79 4.0 ± 3.87 41.69 ± 1.3 >0.05
Leucocyte (× 103/ml) 8.34 ± 1.64 8.44 ± 1.85 76.1 ± 1.63 >0.05
MCV (fl) 81.30 ± 7.3 80.98 ± 8.0 82.84 ± 5.57 >0.05
MCH (pg) 27.38 ± 2.75 26.9 ± 3.45 28.04 ± 1.98 >0.05
MCHC (%) 33.66 ± 0.81 33.13 ± 1.32 33.86 ± 0.56 >0.05
RDW (%) 13.97 ± 2.29 13.75 ± 1.80 13.14 ± 0.80 >0.05
Thrombocyte (× 103/ml) 302 ± 70.56 312 ± 80.71 305 ± 52.66 >0.05
Lymphocyte (%) 31.75 ± 4.98 33.33 ± 7.86 33.58 ± 8.24 >0.05
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Monocyte (%) 7.00 ± 1.54 6.67 ± 1.23 8.42 ± 3.90 >0.05
Neutrophil (%) 57.83 ± 6.28 57.67 ± 8.82 55.42 ± 10.76 >0.05
Eosinophil (%) 3.42 ± 2.81 2.33 ± 1.44 2.82 ± 2.02 >0.05
ESR hour 1 (mm/h) 14.58 ± 11.0 14.00 ± 11.0 16.08 ± 11.07 >0.05
ESR hour 2 (mm/h) 34.25 ± 20.67 30.75 ± 22.12 32.75 ± 20.63 >0.05
Glucose (mg/dl) 89.17 ± 13.23 94.33 ± 14.67 93.33 ± 16.52 >0.05
Total cholesterol (mg/dl) 177.00 ± 23.33 197.25 ± 24.38 183.67 ± 31.26 >0.05
Triglyceride (mg/dl) 97.08 ± 34.91 149.33 ± 95.34 99.42 ± 53.89 >0.05
AST (mg/dl) 22.81 ± 21.70 19.18 ± 7.80 18.52 ± 3.38 >0.05
ALT (mg/dl) 19.57 ± 25.59 16.13 ± 14.53 16.82 ± 11.96 >0.05
BUN (mg/dl) 8.17 ± 1.68 9.13 ± 3.05 7.83 ± 2.27 >0.05
Creatinine (mg/dl) 0.72 ± 0.0.07 0.78 ± 0.15 0.77 ± 0.14 >0.05
IFN-γ expression (%) 4.52 ± 2.84 3.65 ± 1.54 5.02 ± 2.60 >0.05
CD4+Th (%) 53.49 ± 7.76 49.94 ± 6.94 46.24 ± 5.33 >0.05
CD4+CD25+Treg (%) 13.23 ± 5.99 12.11 ± 2.18 12.44 ± 3.19 >0.05
Table 5 revealed that the administration of 1 × 3, 2 × 3 and 3 ×
3 BCSO SC for 20 days did not affect the levels of AST, ALT,
BUN, and creatinine. The levels of BUN, creatinine, and
ALT/AST of subjects within the normal range. The levels of
BUN, creatinine and AST/ALT after the treatment did not
differ between the experimental groups (p>0.05). ALT and
AST are useful biomarkers of liver function. ALT and AST
values on all treatment groups were in the normal range. In
recent years it was reported that the administration of BCSO
combined with other herbal preparations caused hepatic
dysfunction, but our study indicate that administration for 20
days BCSO does not affect liver function and kidney function.
Expression of IFN-γ and Number of CD4+ Th and
CD4+CD25+ Treg cells analysis
The administration of 1 × 3, 2 × 3 and 3 × 3 BCSO SC for 20
days in healthy subjects did not affect the number of CD4+ Th
cells, CD4+CD25+ Treg cells and expression of IFN-γ in
lymphocytes. Table 5 shows that the BCSO administration for
20 days in healthy subject did not affect the number of CD4+
Th and CD4+CD25+ Treg cells and also expression of IFN-γ
(p> 0.05). BCSO may increase the immune response. Our
preclinical study demonstrated that administration of BCSO
increases macrophage activity and T lymphocytes in rats
exposed by dimethylbenzantracene (DMBA) [17].
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